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Background. In Sweden, both glucose analyzers in accredited laboratories and point-of-care glucose devices are used for gestational
diabetes mellitus (GDM) diagnosis. The aim of this study was to compare the diagnostic performance of the HemoCue Glucose 201
+ (HC201+) and RT (HC201RT) systems with that of the hospital central laboratory hexokinase method (CL) based on lyophilized
citrate tubes, using the isotope dilution gas chromatography-mass spectrometry (ID GC-MS) as reference. Methods. A 75 g oral
glucose tolerance test was performed on 135 women screened positive for GDM. Diagnosis was based on the World Health
Organization 2013 diagnostic thresholds for fasting (n = 135), 1 h (n = 52), and 2 h (n = 135) glucose measurements. Bland-
Altman analysis and surveillance error grids were used to evaluate analytical and clinical accuracy. Results. Significantly more
women were diagnosed with GDM by HC201+ (80%) and CL (80%) than with the reference (65%, P < 0:001) based on fasting
and/or 2 h thresholds, whereas the percentage diagnosed by HC201RT (60%) did not differ significantly from the reference. In
Bland-Altman analysis, a positive bias was observed for HC201+ (4.2%) and CL (6.1%) and a negative bias for HC201RT
(−1.8%). In the surveillance error grid, 95.9% of the HC201+ values were in the no-risk zone as compared to 98.1% for
HC201RT and 97.5% for CL. Conclusions. A substantial positive bias was found for CL measurements resulting in overdiagnosis
of GDM. Our findings suggest better performance of HC201RT than HC201+ in GDM diagnosis. The results may have possible
implications for GDM diagnosis in Sweden and require further elucidation.
1. Introduction
The oral glucose tolerance test (OGTT) is the gold standard
for diagnosis of gestational diabetes mellitus (GDM). In
2015, the Swedish National Board of Health and Welfare
(SNBHW) reviewed the evidence of the current Swedish
and the World Health Organization (WHO) diagnostic cri-
teria for GDM and recommended a shift to the lower
WHO diagnostic thresholds [1]. These are based on the
thresholds from the Hyperglycemia and Adverse Pregnancy
Outcome (HAPO) study that identified pregnancies in which
the risks of various adverse outcomes were increased, with an
adjusted odds ratio of 1.75 compared to mean glucose con-
centrations [2, 3]. Due to the limited evidence base, the
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SNBHW made no recommendations regarding screening or
method of glucose analysis. New in the guidelines was the
explicit limitation of glucose measurements in venous blood
samples. GDM screening strategies and diagnostic
approaches have varied in Sweden over the years [4]. Thresh-
olds have been based on either venous or capillary blood
sampling, and for glucose analysis, either hospital laboratory
methods or point-of-care (POC) glucose instruments have
been used. The HemoCue Glucose 201+ (HC201+) and
HemoCue Glucose 201 RT (HC201RT) systems (HemoCue,
Ängelholm, Sweden) are examples of such methodology
and are widely used in Sweden for GDM diagnostic purposes.
There has been doubt among healthcare professionals in
Sweden as to whether to implement the new lower thresh-
olds, as the number of women expected to be diagnosed with
GDM would increase considerably [5], raising concerns over
the clinical management and the associated economic costs.
To address this reluctance, members of the former expert
group appointed by the SNBHW to review the current
GDM guidelines agreed to facilitate the transition to new
criteria by means of a trial. Eventually, a stepped-wedge
randomized controlled trial was designed, the CDC4G
(Changing Diagnostic Criteria for the Diagnosis of
Gestational Diabetes) trial (study ID ISRCTN41918550,
15/12/2017), with the aim to evaluate the clinical and health
economic impacts of changing diagnostic criteria for GDM
in Sweden [6]. The results of the trial are currently under
evaluation and will be presented elsewhere.
Recruitment to CDC4G took place during 2018. By this
time, all participating centers had changed to venous blood
sampling during the diagnostic OGTT but otherwise contin-
ued their usual screening approach. The antenatal center in
Malmö was one of 11 centers that agreed to participate. In
Malmö, blood samples obtained during the diagnostic OGTT
were analyzed by the hospital laboratory method. In parallel,
glucose was measured by HC201+ to give a preliminary
immediate result to the women. In the introductory months
of the recruitment, it was observed that samples analyzed
by the hospital laboratory method resulted in somewhat
higher glucose concentrations than those analyzed by
HC201+. This prompted us to undertake a substudy compar-
ing the diagnostic value of the HemoCue Glucose 201 sys-
tems and the current hospital laboratory method for
glucose measurement, with that obtained by a gold standard
technique, i.e., the isotope dilution gas chromatography-
mass spectrometry (ID GC-MS).
2. Material and Methods
2.1. Study Population. In Malmö, screening for GDM with a
75 g OGTT is offered to all women in the twenty-eighth week
of gestation at their local antenatal clinic, and also in gesta-
tional week 12 if they have a history of GDM or macrosomia
in previous pregnancies, a first-degree relative with diabetes,
or bodymass index ðBMIÞ ≥ 35 kg/m2. The diagnostic cri-
teria for GDM are a slight modification of those recom-
mended by the European Association for the Study of
Diabetes defining GDM as a fasting capillary plasma glucose
concentration of ≥ 7.0mmol/L and/or a 2 h capillary plasma
glucose concentration of ≥ 10.0mmol/L [7]. The HemoCue
Glucose 201 systems are used to perform immediate analysis
of blood glucose concentrations. To ascertain the quality of
the individual testing, double sampling is used with accep-
tance of a divergence of ≤ 0.3mmol/L. In the clinical setting,
the highest test result is regarded as the diagnostic value.
During the recruitment period to the CDC4G study, women
who screened positive for GDM at their local antenatal clinic
in the catchment area of Malmö were referred to the special-
ist antenatal clinic at the hospital for a diagnostic OGTT. All
women referred from the beginning of March to the end of
December 2018 were eligible for inclusion in the present
study. Altogether, 135 out of 149 eligible women underwent
an OGTT according to the study protocol as outlined below.
Reasons for nonparticipation was refusal (n = 4), nonfasting
state (n = 3), impossible to insert a venous cannula (n = 6),
and miscarriage (n = 1). Between March and August 2018,
glucose concentrations were determined at fasting and 2h
after the glucose load, and after randomization to switching
to the WHO 2013 criteria (September–December 2018), a
1 h sample was added according to the protocol of the
stepped-wedged study design. For the purpose of the present
study, we used the following thresholds to define GDM for
the whole study period: fasting glucose ≥ 5:1mmol/L, and/or
1 h glucose ≥ 10:0mmol/L (if taken), and/or 2 h glucose ≥
8:5mmol/L.
The study protocol was approved by the Ethics Commit-
tee of Uppsala University (2016/487/2). All the women who
were included received written information about the study
and signed a written informed consent document.
2.2. Study Procedure and Blood Collection. A standard 75 g
OGTT was performed in the morning after overnight fasting,
by either one of two specially trained midwives. A venous
cannula was inserted into an antecubital vein. At the respec-
tive time point of the OGTT, three blood samples were taken
for determination of glucose concentrations as described
below.
2.2.1. ID GC-MS. The first sample was collected into a lith-
ium heparin tube with gel and immediately centrifuged at
2,000 g for 10min (Sigma 2-6 E Laboratory Centrifuge).
After centrifugation, the plasma was transferred into a
microtube without additives and stored at −20°C until analy-
sis. This sample was used as the reference standard for the
study. All samples were labeled with a code number, and
analyses were performed blind.
(1) Apparatus. The instrument used for GC-MS analysis was
a Shimadzu GC-2010 Plus gas chromatograph with a
Shimadzu AOC-20s autosampler and a Shimadzu AOC-20i
autoinjector. The detection was done with a Shimadzu
QP2020 EI single quadrupole detector. The separation was
done with a 30m × 0:25mm Rxi-5ms fused-silica column
coated with a 0.25μm film (Restek Corporation, Bellefonte,
PA). The carrier gas was helium. The injector was in split
mode, and the injector temperature was kept at 270°C. The
oven temperature gradient was ramped from 80°C to 300°C
at 40°C/min. The derivatives of glucose and [13C6]-glucose
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eluted after ~5.9–6.1min. The column transfer line to the ion
source was kept at 260°C. Selected ion monitoring was car-
ried out with acquisition of ions at m/z 314.0 and 242.1 for
unlabeled glucose and acquisition of ions at m/z 319.0 and
246.1 for [13C6]-labeled glucose.
(2) Standard Solutions and Controls. Standard solutions
were prepared from glucose Standard Reference Material
917c (D-Glucose; NIST, Gaithersburg, MD). The standard
solutions were prepared by weighing the reference material
with an AX105 Delta Range analytical balance (Mettler
Toledo) and dilution with deionized water using volumetric
pipettes and volumetric flasks to six different concentrations:
1, 3, 6, 10, 20, and 30mmol/L. To assess the accuracy of the
method, Standard Reference Material 965b (glucose in frozen
human serum; NIST) Level 1 to Level 4 was used [8]. The
defined value at each level is 33.08mg/dL (1.83mmol/L),
75.56mg/dL (4.20mmol/L), 118.50mg/dL (6.58mmol/L),
and 294.50mg/dL (16.36mmol/L), respectively. The aver-
ages for each level from the thirteen occasions deviated by
−1.8%, −0.5%, −1.1%, and −0.3%, respectively, from the
defined values.
(3) Internal Standard Solution. Internal standard solution
was prepared by weighing [13C6]-glucose (Cambridge Iso-
tope Laboratories, Andover, MA) with an AX105 Delta
Range analytical balance (Mettler Toledo) and dilution with
deionized water using volumetric pipettes and volumetric
flasks, to a final concentration of 1.0mmol/L.
(4) Chemicals. All chemicals were of analytical grade. Hydrox-
ylamine hydrochloride and pyridine were from Sigma-
Aldrich. Ethanol was from Acros Organics. Methanol was
from Fluka andHoneywell. Chloroformwas fromHoneywell.
(5) Sampling Equipment and Analytical Procedure. The anal-
yses were distributed over 11 months on thirteen different
occasions between March 27, 2018, and January 24, 2019.
The ID GC-MS method used was performed essentially as
previously described by Hannestad and Lundblad for glucose
in whole blood [9]. The samples were thawed on a roller
mixer at room temperature. The plasma was then transferred
to Eppendorf tubes and centrifuged at 2,000 g for 10min
(Sigma 1-14 Laboratory Centrifuge). This step was intro-
duced to prevent clots from affecting further analysis. The
plasma sample (40μL) and the internal standard solution
(160μL) were collected with a Microlab 540B diluter/dispen-
ser (Hamilton Company, Reno, NV). Plasma samples were
diluted with internal standard solution and transferred to
blood collection tubes (BD Vacutainer, Z, 5mL). The tubes
were shaken thoroughly. The samples were left on the bench
at room temperature for 1–2h, and 0.8mL of ethanol/metha-
nol solution (50/50) was added to them for deproteinization.
The tubes were shaken thoroughly. The samples were then
left on the bench for 30–45min, followed by centrifugation
for 10min at 2,000 g (Eppendorf Centrifuge 5416). A propor-
tion of the upper phase (0.5mL) was transferred to a deriva-
tization tube (16 × 55mm, with screw cap) and dried without
the cap, under a stream of air on a heating block (Techne
Sample Concentrator, Dri-Block 3D) at 50°C for 30min.
Hydroxylamine hydrochloride solution (150μL, 0.2M) in
pyridine was added to the tube, and the glucose was con-
verted to aldonitrile derivatives by heating at 90°C for
40min (Heraeus VT 5042 EK heating cabinet). After cooling,
the derivatives were acetylated by addition of 200μL acetic
anhydride, followed by heating at 90°C for 60min. The sam-
ples were then evaporated to dryness in air at 50°C, and the
residues were dissolved in 0.5mL chloroform. One hundred
fifty μL of the solution was diluted with 1,350μL chloroform
in vials (1.5mL GC vials). The vials were capped and loaded
into the autosampler. Standard solutions and controls were
diluted and analyzed in the same way as the plasma samples.
The injector was programmed to inject 1μL of each sample
into the gas chromatograph. All samples, standards, and con-
trols were measured in duplicate, and the results were quan-
tified by measuring the peak areas form/z 314.0 for unlabeled
glucose and m/z 319.0 for [13C6]-labeled glucose. The m/z
242.1 and 246.1 ions were used as qualifier ions and served
to confirm the identity of the glucose and [13C6]-labeled glu-
cose derivatives. Calibration curves were produced, and the
concentration of glucose in unknown samples was calculated
from a linear regression fit of the peak area ratios (m/z
314.0)/(m/z 319.0). The results were noted as the average of
the duplicates.
2.2.2. HemoCue Glucose 201. The second sample was col-
lected into an EDTA tube. From this sample, a small amount
of blood was placed on the inside of the respective cuvette
folder for simultaneous and immediate analysis with
HC201+ and HC201RT. The procedure was repeated for a
duplicate test. All calculations were performed on mean
values from the duplicates. Mean imprecision (CV%) of the
duplicate samples was 2.5 for HC201+ and 2.9 for HC201RT.
The HemoCue systems use a photometric technique for glu-
cose analysis that is traceable to ID GC-MS [9]. The instru-
ment automatically converts blood glucose concentrations
to plasma glucose concentrations using a conversion factor
of 1.11 [10]. The major difference between the two systems
is that the 201+ cuvettes must be kept at 4–8°C whereas the
201RT cuvettes can be kept at room temperature and there-
fore have a different design, which excludes the possibility
of prereaction at room temperature. Two different lot
numbers of HC201+ and HC201RT cuvettes were used in
the study, with a switch during the summer. The instru-
ments were checked every week with a calibration fluid
supplied by the company (Gluco Trol-NG). A log was kept
and there were no discrepancies. Participation in external
quality assessment (EQA) schemes from Equalis (a pro-
vider of EQA for clinical laboratory investigations in Swe-
den) took place on a monthly basis. The median (range)
percentage deviation from the assigned glucose values
(6.8–15.0mmol/L) was 1.2 (–2.1 to +4.4) for HC201+
and 2.0 (–1.7 to +8.1) for HC201RT.
2.2.3. Hospital Central Laboratory Hexokinase Method. The
third sample was collected into a VACUETTE® FCMix Tube
(Greiner Bio-One, containing a lyophilized mixture of
Na2EDTA, sodium fluoride, citric acid, and sodium citrate)
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and was kept at room temperature until analysis within 3–
4h. The midwife delivered the samples to the laboratory
directly after completion of the OGTT. Glucose was analyzed
on a Cobas 8000 modular analyzer (Roche Diagnostics Ltd.,
Rotkreuz, Switzerland) by a hexokinase method (hereon
referred to as CL) traceable to the glucose ID GC-MS. The
method has shown a mean imprecision (CV%) of 1.0 and
1.1 at plasma glucose levels 3mmol/L and 20mmol/L,
respectively (n = 50). The laboratory is accredited according
to SS-EN ISO 15189 and participates in interlaboratory com-
parison schemes from Equalis (https://www.equalis.se/en/).
All women had their BMI calculated at their first antena-
tal visit. Clinical and sociodemographic details were recorded
at the time of the diagnostic OGTT at the hospital.
2.3. Statistical Analysis. All comparisons were performed
with ID GC-MS measurements as the reference. Normality
was assessed visually and by the Shapiro-Wilk test. Differ-
ences in mean glucose concentrations were determined using
the paired Student t-test. The impact of the different methods
of glucose analysis on the proportions of women diagnosed
with GDM was determined by the McNemar test for corre-
lated proportions. Bonferroni correction was used to adjust
for repeated comparisons. Pearson’s test was used for estima-
tion of correlations.
Modified Bland-Altman analysis was used to compare
the differences between glucose values obtained by each
method and the reference method with glucose concentra-
tions obtained by the reference method. Surveillance error
grid analysis was performed for each method of glucose anal-
ysis and was compared with the reference measurements
according to the methodology described by Klonoff et al.
[11], using the surveillance error grid software copyrighted
by the University of Virginia (Charlottesville, VA) and avail-
able through the Diabetes Technology Society website at
http://www.diabetestechnology.org/SEGsoftware [12]. The
surveillance error grid displays clinical risks on a continuous
color-coded scale relevant to clinical practice as perceived by
diabetes experts.
The International Organization for Standardization
(ISO) has been used by regulatory agencies to determine
whether a blood glucose meter is sufficiently accurate to be
marketed commercially for the use of people with diabetes.
The current ISO 15197: 2013 accuracy criteria require that
≥95% of all meter results fall within ±0.83mmol/L
(±15mg/dL) or ±15% of the reference results at glucose con-
centrations of <5.55mmol/L (<100mg/dL) or ≥5.55mmol/L
(≥199mg/dL), respectively [13]. Comparison of the surveil-
lance error grid with ISO 15197: 2013 using computer-
simulated pairs with realistic error distribution suggests that
a device with ≤3% errors outside the surveillance error grid
no-risk “green” zone would meet the ISO requirements of
≤5% data pairs outside the 0.83mmol/L or 15% standard
limits, while higher percentages outside the surveillance error
grid no-risk zone would indicate noncompliance with the
standard [12].
IBM SPSS Statistics 24 for Windows (IBM Corporation,
Armonk, NY) was used for analysis. Two-sided P values less
than 0.05 were considered to be statistically significant.
3. Results
The mean age of the 135 women studied was 32:6 ± SD 5.4
years; the mean BMI was 26:9 ± 5:2 kg/m2; the median gesta-
tional age was 30.1 (range 12.3–37.3) weeks; the median
hemoglobin concentration was 116.9 (93–144) g/L; 33.3%
were nulliparous; 5.2% smoked; 44.4% were of European ori-
gin (half of them Swedish); and 55.6% were of non-European
origin (with Arab and Asian origin being the largest groups).
Table 1 shows a comparison of the mean glucose results
for HemoCue and CL measurements with those obtained
by the reference method (ID GC-MS). HC201+ resulted in
higher mean glucose concentrations than those obtained by
HC201RT (P < 0:001), with a similar trend before and after
the switch of lot numbers during the summer (data not
shown).
Table 2 is a comparison of the number of abnormal
results for the fasting, 1 h, and 2h samples for HemoCue
and CL measurements with the number of abnormal results
from the reference method. The best diagnostic performance
relative to the reference was found for HC201RT.
Glucose concentrations at fasting, 1 h, and 2h corre-
lated significantly with the reference method (P < 0:001)
for all the measurements: r = 0:87, 0.95, and 0.97, respec-
tively (HC201+); r = 0:87, 0.96, and 0.97, respectively
(HC201RT); and r = 0:96, 0.97, and 0.98, respectively (CL).
Modified Bland-Altman plots for fasting and 2h glucose
measurements for the different methods of glucose analysis
are shown in Figure 1. Table 3 is a summary of the overall
results of the modified Bland-Altman analysis, comparing
the difference (glucose value obtained by each method minus
the reference value) with the reference value. All three
methods met the ISO 15197: 2013 accuracy standard of
≥95% compliant pairs [13]. The numbers of compliant pairs
were 309 (97.5%) for HC201+, 315 (99.4%) for HC201RT,
and 309 (97.5%) for CL. However, in the surveillance error
grid analysis (Figure 2), 95.9% of the HC201+ values were
within the no-risk (deep green) zone, as compared to 98.1%
of the HC201RT values and 97.2% of the CL values. The
remaining values were within the slight-risk zone (light
green), indicating noncompliance with the ISO standard for
HC201+ as predicted by Kovatchev et al. [12].
There were no significant correlations between hemoglo-
bin concentrations and glucose concentrations obtained by
Table 1: Comparison of mean glucose concentrations (mmol/L)
between each method and the reference method.
Fasting (n = 135) 1 h (n = 52) 2 h (n = 135)
ID GC-MS 4:9 ± 0:6 10:0 ± 1:7 8:9 ± 1:8
HC201+ 5:1±0:5∗∗∗ 10:5±1:7∗∗∗ 9:1±1:8∗∗∗
HC201RT 4:8±0:6∗∗ 10:1 ± 1:6 8:6±1:7∗∗∗
CL 5:2±0:6∗∗∗ 10:8±1:8∗∗∗ 9:4±1:9∗∗∗
Data are mean ± SD. ∗∗P < 0:01 and ∗∗∗P < 0:001 compared to ID GC-MS
(paired Student t-test using Bonferroni correction). CL: central laboratory;
HC201+: HemoCue 201+; HC201RT: HemoCue 201 RT; ID GC-MS:
isotope dilution gas chromatography-mass spectrometry.
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either one of the two HemoCue systems at any time point of
the OGTT (data not shown).
4. Discussion
Using the WHO 2013 thresholds for the diagnosis of GDM,
we found that HC201RT was more accurate than both
HC201+ and CL glucose measurements in making the diag-
nosis of GDM in women screened positive with a universal
75 g OGTT based on capillary blood sampling and modified
EASD criteria [7]. Furthermore, in modified Bland-Altman
analysis, HC201RT showed the best agreement with the
reference method. CL measurements consistently yielded
higher glucose values than the reference method, resulting
in a substantial bias in the Bland-Altman analysis and an
increased number of women diagnosed with GDM. The find-
ings may have possible implications for the clinical setting of
GDM diagnosis in Sweden.
Optimal conditions for glucose measurements are crucial
in GDM diagnosis. Unsatisfactory glycolysis inhibition may
lead to diagnostic misclassification. Thus, a key component
of the HAPO study was the standardization of research con-
ditions with particular attention being paid to sample han-
dling and centralization of glucose measurements [14].
However, in 2011, the laboratory standards applied in the
HAPO study were revised. To inhibit glycolysis more effec-
tively, it was recommended that the fluoride sample tube
(kept on ice) should be centrifuged within 30min and not
within 60min as previously recommended [15]. If this is
not possible, tubes containing a rapidly effective glycolysis
inhibitor, such as citrate buffer, should be used [15]. The
acidification of whole blood with citrate buffer seems to stop
glycolysis immediately [16]. Gambino et al. showed that the
mean glucose concentrations decreased by 0.3% and 1.2%,
respectively, 2 h and 24h after collection at room tempera-
ture [17]. At present, most accredited laboratories in Sweden
have changed to tubes with lyophilized citrate. Due to the
very effective inhibition of glycolysis, this change may lead
to a more accurate estimation of plasma glucose concentra-
tions and so to overdiagnosis of GDM if diagnostic thresh-
olds are based on the HAPO study where less efficient
inhibition of glycolysis was used [18, 19]. This highlights
the importance of the ongoing CDC4G trial to define diag-
nostic cut-off points for the diagnosis of GDM in a contem-
porary Swedish setting.
Not surprisingly, we found a strong correlation between
CL measurements and those obtained using the reference
method. Likewise, the Bland-Altman plots indicated a high
precision of the method. However, the finding of an overall
positive bias of 6.1% for CLmeasurements, most pronounced
for 1 h measurements, was more than expected. The calcu-
lated bias for CL measurements at the different time points
of the OGTT (Table 3) correspond to fasting, 1 h, and 2h
values of 5.4mmol/L, 10.8mmol/L, and 9.0mmol/L at diag-
nostic cut-off points, respectively, leading to a proportional
increase in GDM cases (Table 2). Other groups have reported
a small positive bias for glucose concentrations measured in
citrate buffer tubes when compared to glucose values mea-
sured in conventional tubes under optimal preanalytical con-
ditions [16, 20, 21]. However, still other groups have reported
good agreement in glucose results between the different types
of collecting systems [22–24]. A suboptimal inhibition of gly-
colysis in the reference tube may account for some of these
differences, considering that glycolysis takes place within
minutes from venipuncture until plasma is separated [20].
For the present study, the reference tube was centrifuged
immediately with no delay, but it cannot be excluded that
some glycolysis did take place, as we did not have access to
chilled centrifugation. Inaccuracy of the reference method
should also be considered to be a potential source of bias.
However, only minor deviations from reference values were
found when the accuracy was assessed in certified values
(NIST) at four levels.
To comply with international guidelines [15], although
not mandatory, eight of the eleven centers participating in
the CDC4G trial used accredited laboratory methods for glu-
cose measurements during the study period [6]. All methods
(Roche Cobas, Beckman Coulter Au, Siemens Advia, or
Abbott Architect) were based on hexokinase [6]. The samples
were drawn in EDTA tubes with citrate and sodium fluoride
as an antiglycolytic agent. During the study period (2018),
the mean bias in relation to results from reference measure-
ment procedures in EQA was 3.7% for all the participating
hospital laboratories in CDC4G and 3.2% for the hospital
laboratory in Malmö (Equalis, Uppsala). The reasons for this
positive bias is unclear, but may possibly relate to a remain-
ing inaccurate calibration of instruments by the manufac-
turers as once pointed out by Gambino [25], and consistent
with a report by Miller et al. [26].
To our knowledge, this is the first study to evaluate
lyophilized citrate tubes for the diagnosis of GDM in a
Table 2: Comparison of abnormal test results between each method and the reference method.
Fasting (n = 135) 2 h (n = 135) Fasting and/or 2 h (n = 135) 1 h (n = 52) Fasting and/or 1 h (n = 52) Overalla (n = 52)
ID GC-MS 45 (33) 71 (54) 86 (65) 24 (47) 28 (55) 35 (70)
HC201+ 64 (47)∗∗∗ 89 (66)∗∗∗ 108 (80)∗∗∗ 34 (67)∗ 36 (71) 44 (85)
HC201RT 41 (30) 69 (51) 82 (61) 22 (43) 27 (53) 35 (67)
CL 75 (56)∗∗∗ 86 (64)∗∗∗ 107 (80)∗∗∗ 38 (73)∗∗∗ 42 (81)∗∗∗ 45 (87)∗
Data are n (%). Fasting cut-off of ≥5.1 mmol/L; 1 h cut-off of ≥10mmol/L; 2 h cut-off of ≥8.5 mmol/L. aFasting and/or 1 h and/or 2 h. ∗P < 0:05, ∗∗P < 0:01, and
∗∗∗P < 0:001 compared to ID GC-MS (McNemar test for correlated proportions using Bonferroni correction). Missing values were below 4% for all
measurements. CL: central laboratory; HC201+: HemoCue 201+; HC201RT: HemoCue 201 RT; ID GC-MS: isotope dilution gas chromatography-mass
spectrometry.
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Figure 1: Modified Bland-Altman plots of fasting and 2 h glucose measurements for HC201+ (a), HC201RT (b), and CL (c). The dashed lines
show the range containing the mean of the differences ± 1:96 SD. CL: central laboratory; HC201+: HemoCue 201+; HC201RT: HemoCue 201
RT; ID GC-MS: isotope dilution gas chromatography-mass spectrometry.
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clinical setting, in a rather large number of women at a high
risk of GDM using WHO 2013 diagnostic thresholds. Previ-
ous studies have shown no or only a small increase in the
diagnoses of GDM with the use of lyophilized citrate tubes
[22, 24]. However, these studies were based on smaller num-
bers of women with generally lower glucose levels and few
patients close to the diagnostic cut-off levels. A mean differ-
ence of 0.3mmol/L fasting and up to 0.8mmol/L postload,
as noted in the present study, will lead to overdiagnosis of
GDM in the large proportion of women who have glucose
concentrations close to the diagnostic cut-off points.
Glucose measurement by a POC technique for the diagno-
sis of GDM is useful for both the women and their caregivers.
This saves time, reduces costs, and reduces some of the prea-
nalytical errors. Furthermore, it has the advantage of provid-
ing a diagnosis immediately so that treatment can start
promptly. In previous comparisons with laboratory glucose
measurements, the HemoCue Glucose 201 system has been
found to be accurate [27, 28]. When HC210RT was compared
to accredited hospital laboratory methods in subjects with cor-
onary artery disease in a European survey, the Bland-Altman
plot showed small differences and, in contrast to our findings,
a tendency of higher glucose measurements for HC201RT
than for hospital laboratory measurements [28]. The −1.8%
bias noted for the HC201RT instrument in the present study
is close to the 2.2% limit for acceptable bias according to inter-
national guidelines [15]. However, HC201+ performed less
well than HC201RT in Bland-Altman and surveillance error
grid analysis, and plasma glucose recordings were consistently
higher than those by HC201RT were. This contrasts with a
previous study showing only minor deviations between the
two devices [27].We postulated that variations between differ-
ent lot numbers of cuvettes might have a role in these results.
However, similar deviations in glucose values between the two
devices were found before and after the change in lot numbers
during the summer. Moreover, good agreement between dif-
ferent HemoCue devices of the same model and lot numbers
has been demonstrated previously [29]. According to the
manufacturer, it can be expected for both devices to have a
lot-to-lot as well as an instrument-to-instrument variation of
less than 0.2mmol/L or a total system variation of less than
0.3mmol/L at normal glucose levels. In the present study,
the deviations in mean values between the two devices were
most pronounced for 1h and 2h values, which may indicate
a larger system variation at higher glucose levels. Furthermore,
although we followed the manufacturer’s instructions for stor-
age of the HemoCue201+ cuvettes at 4–8°C, we cannot
exclude the possibility that this potential source of error may
have affected the results.
The constant factor 1.11 used by the HemoCue system
for automatic conversion of whole blood glucose values to
equivalent plasma glucose values is based on the relationship
at normal hematocrit (0.43) [10]. Hematocrit levels at the
extremes will therefore have an effect on the results [29].
Considering the relative anemia that occurs in pregnancy
due to hemodilution, the conversion factor 1.11 may not be
optimal [30]. Using hemoglobin concentrations (range 93–
144 g/L) as a surrogate measure of hematocrit, we found no
correlation with the HemoCue glucose results in the present
study group. However, this does not preclude an effect at the
individual level. A bias of 5% could be expected at the hemat-
ocrit extremes 0.25 and 0.6, and a conversion factor of 1.06
and 1.16, respectively, would have been more appropriate
to use under these circumstances [10].
A major strength of this study was the access to the ID
GC-MS technology as a reference method. Furthermore,
two specially trained midwives conducted the study under
standardized conditions in a clinical setting. A possible limi-
tation of this study was that we did not undertake experi-
ments to explore the reasons for the high bias of CL
measurements, such as head-to-head comparisons with ID
GS-MS in samples collected and handled under identical
conditions. Unfortunately, the reference method was not
included in the EQA schemes from Equalis. Owing to the fact
that the study was confined to a single center in the CDC4G
trial, the results cannot automatically be extrapolated to
other regions of Sweden using other models for GDM screen-
ing and diagnostic procedures.
5. Conclusions
Our results showed substantial positive bias from the hospital
laboratory procedure for glucose measurements resulting in
overdiagnosis of GDM. Furthermore, HC201RT showed
better agreement with the reference than HC201+. The
HemoCue Glucose 201 systems are widely used in Sweden
Table 3: Summary of modified Bland-Altman comparison.
Valid
samples (n)
Bias
(%)
MARD
(%)a
CV
(%)b
95% limits of
agreement
Lowerc Upperd
HC201+
Fasting 135 4.3 6.3 6.5 –7.6 16.5
1 h 50 4.9 5.8 5.2 –3.7 14.6
2 h 132 3.5 5.1 5.6 –6.7 13.4
Overall 317 4.2 5.8 6.0 −7.6 15.9
HC201RT
Fasting 135 –1.8 5.1 6.1 –12.2 9.4
1 h 50 0.3 3.4 4.3 –6.5 8.3
2 h 132 –2.7 4.8 5.2 –12.1 6.7
Overall 317 −1.8 4.7 5.6 −12.8 9.2
CL
Fasting 134 5.9 6.0 3.8 0.0 13.0
1 h 51 8.1 8.2 4.3 0.7 14.8
2 h 132 5.7 6.0 4.3 –0.9 15.1
Overall 317 6.1 6.3 4.2 −2.1 14.3
Modified Bland-Altman analysis comparing the difference (glucose value
obtained by each method–reference value) with the reference value. The
bias is the mean relative difference as a percentage of the reference value. A
bias of 5% means that the value is on average 5% higher than the reference
value. aMean absolute relative difference as a percentage of the reference
value. bStandard deviation of the bias. cLower 95% limits of agreement
define bias −1.96 ∗ CV. dUpper 95% limits of agreement define bias +1.96
∗ CV. CL: central laboratory; CV: coefficient of variation; HC201+:
HemoCue 201+; HC201RT: HemoCue 201 RT; MARD: mean absolute
relative difference.
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for GDM screening and diagnosis. Our findings support the
continuous use of HC201RT in GDM diagnostics. However,
more work on the HemoCue systems across hematocrit levels
in pregnancy is desirable. Finally, there is an urgent need to
explain the reasons for the high bias of the CL glucose mea-
surements and to confirm our results in different settings of
GDM diagnosis in Sweden.
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Figure 2: Surveillance error grid analysis for HC201+ (a), HC201RT (b), and CL (b) relative to the reference method of glucose measurement.
The color-coded risk zone definition is according to Klonoff et al. [11]. CL: central laboratory; HC201+: HemoCue 201+; HC201RT:
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